Lansoprazole is a ATP4A (H+,K+-ATPase) inhibitor (IC50 = 6.3 μM) that displays antisecretory and antiulcer activity. Inhibits gastric acid secretion (IC50 = 0.09 µM for histamine-induced acid formation) and reduces gastric lesion formation induced by a variety of ulcerative stimuli. Antibacterial against Helicobacter pylori in vitro. Also blocks swelling-dependent chloride channel (ICI swell) in NIH3T3 fibroblasts. Lansoprazole is more potent than omeprazole (sc-202265).
Satoh et al (1989) Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats. J.Pharmacol.Exp.Ther. 248 806. Schmarda et al (2000 The gastric H,K-ATPase blocker lansoprazole is an inhibitor of chloride channels. Br.J.Pharmacol. 129 598. Matheson and Jarvis (2001) Lansoprazole. Drugs 61 1801.
See how others have used Lansoprazole (CAS 103577-45-3). Click on the entry to view the PubMed entry .
PMID: # 25141173 Novotna, A. et al. 2014. PLoS ONE. 9: e105580.
PMID: # 24887303 Novotna, A. et al. 2014. PLoS ONE. 9: e98711.
PMID: # 23652407 Tamraz, B. et al. 2013. Pharmacogenet. Genomics. 23: 355-64.
PMID: # 32153057 Andrologia. e13564.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2021 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.